Market Overview

Does Reward Potential Still Outweigh The Risk In Akorn Shares?

Does Reward Potential Still Outweigh The Risk In Akorn Shares?

Deutsche Bank downgraded Akorn, Inc. (NASDAQ: AKRX) to Hold from Buy as the stock has recovered since the post-third quarter correction. According to Deutsche Bank, further upside will depend on “hard-to-call dynamics of new product approvals vs. base business erosion.”

Akorn has a large number of ANDAs (generic applications) at the FDA that should help offset a shrinking base. But, analyst Gregg Gilbert noted that "this dynamic could be especially challenging over the next 6–12 months in light of expected significant share erosion for the very high-margin ephedrine line (~19 percent of revenue)."

Analyst's Reaction

Meanwhile, Gilbert cut his 2017 revenue estimate to $1.04 billion (from $1.15 billion) and 2018 revenue to $1.12 billion (from $1.18 billion) to reflect significant erosion for ephedrine. The analyst also trimmed his gross margin assumptions by about 500bp to reflect the mix impact of lower ephedrine sales.

As such, the analyst’s 2017 EPS view comes down to $1.57 (from $2.15) and 2018 EPS to $1.79 (from $2.23).

“For new launches, we model $45 million in 2017 (AKRX expects $30 million–60 million) and $100 million in 2018+. For the base business (ex-ephedrine and new launches), we model 5 percent annual erosion in 2018+,” Gilbert wrote in a note.

At last check, shares of Akorn had fallen 6.86 percent to $22.46. The analyst cut the target price by $4 to $24.

Related Link: The Market In 5 Minutes

Related Link: 15 Biggest Mid-Day Losers For Monday

Latest Ratings for AKRX

Sep 2019MaintainsHold
Mar 2019Initiates Coverage OnHold
Oct 2018UpgradesNeutralOverweight

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (AKRX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at